- July 18, 2008
- Taiho Pharmaceutical Co., Ltd.
License agreement with Sanofi-Aventis on TS-1 is terminated
Taiho announces today that sanofi-aventis is returning its territory rights to Taiho Pharmaceutical Co., Ltd. for the development and commercialization of the oral anti-cancer agent S-1.
Taiho will pursue further development of S-1 outside of Japan with gastric cancer included.
S-1 is an oral fluorouracil anticancer product that combines 3 pharmacological agents in a certain ratio: tegafur which is a pro-drug of 5 fluoro-uracil; gimeracil (5-chloro-2,4 dihydropyridine (CDHP)) which inhibits dihydropyrimidine dehydrogenase (DPD) enzyme activity; and oteracil (potassium oxonate (Oxo)) a gastrointestinal side effects corrector.
S-1 has been commercialized in Japan by Taiho Pharmaceuticals since 1999 for the treatment of gastric, colorectal, head and neck, non-small cell lung, metastatic breast, pancreas and biliary tract cancers.
Information in this news release was current as of the original release date.